Move Over Botox: New Neurotoxin Coming to the United States
A New Neurotoxin Is Coming to the U.S.
Botox Cosmetic, Dysport and Xeomin are the heavy hitters in town, but now there is a new addition coming to the family of neurotoxins.
Known as Nabota and manufactured by the Korean company, Daewoong Pharmaceutical, the brand new neurotoxin is anticipated to be available in doctor’s offices by the end of 2018.
According to New Beauty, Nabota is currently in the FDA-approval process for the treatment of frown lines in adults.
This marks the first ever attempt by a South Korean company to introduce its own botulinum toxin to the United States market.
“Submission of the BLA within three years of the first study enrollment speaks of our experience, drive and commitment. We are excited to move one step closer to its commercial launch,” Chris Marmo, president of Beauty for Alphaeon, said in a press release.
If approved, would become the first Korea-made BTX product to hit the US market, which makes up the largest portion of the global botulinum toxin market that is projected to reach $6.6 billion by 2022, according to market intelligence firm Global Industry Analysts Inc.
“This is a very exciting development for plastic surgeons and dermatologists. Botox is, and has been for a long time, the king of cosmetic treatments—for good reason, too!,” said Troy, MI, plastic surgeon Anthony Youn, MD.
“Although at this time we don’t know how Alphaeon’s new botulinum toxin stacks up against Botox, any competition in this market is a good thing. I’m excited to try it when it comes out.”
With all the excitement of another neurotoxin coming to the states, Daewoong Pharmaceuticals are not stopping there.
“It is very encouraging that NABOTA, developed by indigenous technology, is poised to gain ground in Latin America, the second largest beauty market in the world, as well as the developed countries. We will fully leverage our technological prowess to develop excellent quality products that can be well-received in the global market,” said Kim Cheong-se, the Chief Researcher at the Research Division of Daewoong Pharmaceutical.